公开(公告)号：US11673125B2

公开(公告)日：2023-06-13

申请号：US16314326

申请日：2017-08-18

Applicant: The University of Chicago

Inventor： Wenbin Lin ,  Kuntal Manna ,  Pengfei Ji ,  Takahiro Sawano ,  Zekai Lin

IPC: B01J31/02 ,  B01J27/128 ,  B01J31/12 ,  B01J37/04

CPC classification number: B01J27/128 ,  B01J31/121 ,  B01J37/04 ,  B01J2231/44 ,  B01J2231/643 ,  B01J2231/645 ,  B01J2231/646 ,  B01J2531/845 ,  B01J2531/847

Abstract: Surface hydroxyl groups on porous and nonporous metal oxides, such as silica gel and alumina, were metalated with catalyst precursors, such as complexes of earth abundant metals (e.g., Fe, Co, Cr, Ni, Cu, Mn and Mg). The metalated metal oxide catalysts provide a versatile family of recyclable and reusable single-site solid catalysts for catalyzing a variety of organic transformations. The catalysts can also be integrated into a flow reactor or a supercritical fluid reactor.

公开(公告)号：US20230036839A1

公开(公告)日：2023-02-02

申请号：US17855327

申请日：2022-06-30

Applicant: The University of Chicago

Inventor： Wenbin Lin ,  Christina Chan ,  Wenbo Han

IPC: A61K31/343 ,  A61K47/68 ,  A61P35/00 ,  A61P37/00 ,  A61K45/06

Abstract: Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

公开(公告)号：US20200261403A1

公开(公告)日：2020-08-20

申请号：US16859594

申请日：2020-04-27

Applicant: The University of Chicago

Inventor： Wenbin Lin ,  Christina Chan ,  Wenbo Han

IPC: A61K31/343 ,  A61K47/68 ,  A61P35/00 ,  A61P37/00 ,  A61K45/06

Abstract: Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

公开(公告)号：US20200254095A1

公开(公告)日：2020-08-13

申请号：US16634486

申请日：2018-08-02

Applicant: The University of Chicago

Inventor： Wenbin Lin ,  Kaiyuan Ni ,  Guangxu Lan

IPC: A61K41/00 ,  A61K47/34 ,  A61K33/243 ,  A61K45/06 ,  A61P35/00 ,  A61N5/10

Abstract: Metal-organic layers (MOLs) and metal-organic nanoplates (MOPs) comprising photosensitizers are described. The MOLs and MOPs can also include moieties capable of absorbing X-rays or other ionizing irradiation energy and/or scintillation. Optionally, the photo sensitizer or a derivative thereof can form a bridging ligand of the MOL or MOP. Also described are methods of using MOLs and MOPs in photodynamic therapy, X-ray induced photodynamic therapy (X-PDT), radiotherapy (RT), radiodynamic therapy, or in radiotherapy-radiodynamic therapy (RT-RDT), either with or without the co-administration of another therapeutic agent, such as a chemotherapeutic agent or an immunomodulator.

公开(公告)号：US20240042045A1

公开(公告)日：2024-02-08

申请号：US18022296

申请日：2021-08-23

Applicant: The University of Chicago

Inventor： Wenbin Lin ,  Xiaomin Jiang ,  Wenbo Han ,  Xuanyu Feng

IPC: A61K47/54 ,  A61K47/69 ,  A61K45/06 ,  A61P35/00 ,  C07J43/00

CPC classification number: A61K47/554 ,  A61K47/6929 ,  A61K45/06 ,  A61P35/00 ,  C07J43/003 ,  B82Y5/00

Abstract: Prodrugs that target the low-density lipoprotein receptor (LDLR) and that comprise acid and/or enzyme cleavable acetal- or oxybenzyloxy-linked carbonate or carbamate bonds are described. Also described are core-shell nanoparticles comprising metal-organic framework cores or nanoscale metal bisphosphate coordination polymer cores, and lipid coating layers containing the prodrugs. The nanoparticle core can optionally contain one or more hydrophilic chemotherapeutic agents. The prodrugs and nanoparticles can be used in methods of treating cancer. For instance, the presently disclosed nanoparticles can be used for the co-delivery of multiple chemotherapeutic agents in methods providing increased accumulation of chemotherapeutic agents to a tumor compared to delivery of mixtures of free chemotherapeutic agents.

公开(公告)号：US20230293698A1

公开(公告)日：2023-09-21

申请号：US17927168

申请日：2021-05-24

Applicant: The University of Chicago

Inventor： Wenbin Lin ,  Kaiyuan Ni ,  Taokun Luo ,  Guangxu Lan

IPC: A61K47/52 ,  A61P35/00 ,  A61K31/7088

CPC classification number: A61K47/52 ,  A61P35/00 ,  A61K31/7088

Abstract: Modified metal-organic framework (MOFs) are described that have surfaces with enhanced ability to coordinatively bond to or electrostatically interact with therapeutic agents, such as nucleic acids and small molecules and proteins with phosphate or carboxylate groups. Methods of providing the modified MOFs are described that include replacing strongly coordinating metal oxo cluster capping groups with weakly coordinating capping groups and/or incorporating organic bridging ligands with electron-withdrawing groups. MOFs with surface attached therapeutic agents (e.g., immunotherapeutic agents) prepared from the modified MOFs are also described, along with methods of using the MOFs as to treat cancer, e.g., via radiotherapy-radiodynamic therapy (RT-RDT), either with or without the co-administration of another therapeutic agent, such as a chemotherapeutic agent or an immunomodulator. Thus, the described methods can involve cancer immunotherapy and in situ cancer vaccination.

公开(公告)号：US20200324276A1

公开(公告)日：2020-10-15

申请号：US16314326

申请日：2017-08-18

Applicant: The University of Chicago

Inventor： Wenbin Lin ,  Kuntal Manna ,  Pengfei Ji ,  Takahiro Sawano ,  Zekai Lin

IPC: B01J27/128 ,  B01J31/12 ,  B01J37/04

Abstract: Surface hydroxyl groups on porous and nonporous metal oxides, such as silica gel and alumina, were metalated with catalyst precursors, such as complexes of earth abundant metals (e.g., Fe, Co, Cr, Ni, Cu, Mn and Mg). The metalated metal oxide catalysts provide a versatile family of recyclable and reusable single-site solid catalysts for catalyzing a variety of organic transformations. The catalysts can also be integrated into a flow reactor or a supercritical fluid reactor.

公开(公告)号：US20190314324A1

公开(公告)日：2019-10-17

申请号：US16381774

申请日：2019-04-11

Applicant: The University of Chicago

Inventor： Wenbin Lin ,  Christina Chan ,  Wenbo Han

IPC: A61K31/343 ,  A61K47/68 ,  A61K45/06 ,  A61P35/00 ,  A61P37/00

Abstract: Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

公开(公告)号：US20190209460A1

公开(公告)日：2019-07-11

申请号：US16235752

申请日：2018-12-28

Applicant: The University of Chicago

Inventor： Wenbin Lin ,  Chunbai He ,  Kuangda Lu

IPC: A61K9/00 ,  A61K31/704 ,  A61K31/519 ,  A61K31/4745 ,  A61K31/4188 ,  A61K31/405 ,  A61K31/282 ,  A61K41/00 ,  A61K31/337 ,  A61K31/409

Abstract: Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X-rays and/or scintillation. Optionally, the photosensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and/or inorganic nanoparticles in photodynamic therapy or in X-ray induced photodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and/or one or more chemotherapeutic agent.

公开(公告)号：US20170173572A1

公开(公告)日：2017-06-22

申请号：US15129851

申请日：2015-03-30

Applicant: The University of Chicago ,  The University of North Carolina at Chapel Hill

Inventor： Wenbin Lin ,  Joseph M. Falkowski ,  Takahiro Sawano

IPC: B01J31/16 ,  B01J31/18 ,  C07C45/69 ,  C07C231/02 ,  C07C67/303 ,  C07C41/09 ,  C07D307/93 ,  C07C227/04 ,  B01J31/24 ,  C07C29/44

CPC classification number: B01J31/1691 ,  B01J31/1805 ,  B01J31/182 ,  B01J31/2409 ,  B01J31/2433 ,  B01J31/2447 ,  B01J2531/0205 ,  B01J2531/0263 ,  B01J2531/0266 ,  B01J2531/822 ,  C07C29/44 ,  C07C41/09 ,  C07C45/69 ,  C07C67/303 ,  C07C227/04 ,  C07C231/02 ,  C07C2102/44 ,  C07D307/93 ,  Y02P20/544

Abstract: Metal-organic framework (MOFs) compositions based on chiral phosphine-, chiral oxazoline-, chiral pyridine-, and chiral diene-derived organic bridging ligands were synthesized and then post-synthetically metalated with metal precursors such as Ru and Rh complexes. The metal complexes could also be directly incorporated into the MOFs. The MOFs provide a versatile family of recyclable and reusable single-site solid catalysts for catalyzing a variety of asymmetric organic transformations, including the addition of arylboronic acids to α,β-unsaturated ketones and alkimines, the hydrogenation of substituted alkene and carbonyl compounds, and cyclization reactions. The solid catalysts can also be integrated into a flow reactor or a supercritical fluid reactor.